Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TW001 in early Alzheimer's disease
NL-OMON53963Phase 2Completed
- Sponsor
- Treeway
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing TW001 with Placebo (2 arms). Primary endpoints: Effect on oxidative stress biomarkers and Safety. Started Feb 2023; status: completed.
02
Drugs
TW001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON53963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53963.